These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 19654170)
1. Pseudo-observations in survival analysis. Andersen PK; Perme MP Stat Methods Med Res; 2010 Feb; 19(1):71-99. PubMed ID: 19654170 [TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplantation for leukemia in Europe: regional differences. Report from the Leukemia Working party of the European Group for Bone Marrow Transplantation. Gratwohl A; Hermans J; Barrett AJ; Ernst P; Frassoni F; Gahrton G; Granena A; Kolb HJ; Prentice HG; Vernant JP Bone Marrow Transplant; 1990 Mar; 5(3):159-65. PubMed ID: 2331536 [TBL] [Abstract][Full Text] [Related]
3. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Geskus RB Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575 [TBL] [Abstract][Full Text] [Related]
4. Regression modeling of competing risk using R: an in depth guide for clinicians. Scrucca L; Santucci A; Aversa F Bone Marrow Transplant; 2010 Sep; 45(9):1388-95. PubMed ID: 20062101 [TBL] [Abstract][Full Text] [Related]
5. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124 [TBL] [Abstract][Full Text] [Related]
6. Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution. Katsahian S; Resche-Rigon M; Chevret S; Porcher R Stat Med; 2006 Dec; 25(24):4267-78. PubMed ID: 16960919 [TBL] [Abstract][Full Text] [Related]
8. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate. Fyles GM; Messner HA; Lockwood G; Curtis JE; Rider W; Minden MD; Meharchand JM; Lipton J; Tritchler D; Van Dyk J Bone Marrow Transplant; 1991 Dec; 8(6):453-63. PubMed ID: 1790425 [TBL] [Abstract][Full Text] [Related]
9. Modelling competing risks in cancer studies. Klein JP Stat Med; 2006 Mar; 25(6):1015-34. PubMed ID: 16435339 [TBL] [Abstract][Full Text] [Related]
10. [Bone marrow autotransplant: preliminary results in 20 patients with acute leukemia]. Sierra J; Grañena A; Martí JM; Carreras E; García J; Valls A; Martínez E; Puntí C; Martí-Carvajal A; Rozman C Med Clin (Barc); 1989 Oct; 93(11):401-5. PubMed ID: 2607797 [TBL] [Abstract][Full Text] [Related]
11. [Bone marrow transplantation in the treatment of acute leukemias]. Moiseev SI; Ganapiev AA; Abdulkadyrov KM Ter Arkh; 1996; 68(12):8-10. PubMed ID: 9054052 [TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J; Ringdén O Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365 [TBL] [Abstract][Full Text] [Related]
13. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394 [TBL] [Abstract][Full Text] [Related]
14. Bone marrow transplantation for leukaemia in Europe. Gratwohl A; Hermans J; Lyklema A; Zwaan FE Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):353-60. PubMed ID: 2480274 [TBL] [Abstract][Full Text] [Related]
15. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Klein JP; Andersen PK Biometrics; 2005 Mar; 61(1):223-9. PubMed ID: 15737097 [TBL] [Abstract][Full Text] [Related]
16. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Eapen M; Giralt SA; Horowitz MM; Klein JP; Wagner JE; Zhang MJ; Tallman MS; Marks DI; Camitta BM; Champlin RE; Ringdén O; Bredeson CN; Martino R; Gale RP; Cairo MS; Litzow MR; deLima M Bone Marrow Transplant; 2004 Oct; 34(8):721-7. PubMed ID: 15322568 [TBL] [Abstract][Full Text] [Related]
17. Reduced rank proportional hazards model for competing risks. Fiocco M; Putter H; Van Houwelingen JC Biostatistics; 2005 Jul; 6(3):465-78. PubMed ID: 15831577 [TBL] [Abstract][Full Text] [Related]
18. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686 [TBL] [Abstract][Full Text] [Related]
19. Cumulative incidence in competing risks data and competing risks regression analysis. Kim HT Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278 [TBL] [Abstract][Full Text] [Related]
20. Autologous bone marrow transplantation (ABMT) using unpurged marrow as intensification for first complete remission in acute leukaemia (AL). Kubel M; Helbig W; Schwenke H; Wötzel M; Thierbach V; Standke E; Hoffmann FA Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):493-8. PubMed ID: 2480296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]